文献速递静脉血栓栓塞

上肢深静脉血栓患者的中期结局

Midterm outcomes in patients with upper extremity deep vein thrombosis.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2020-05-23

本研究为单中心回顾性研究,纳入2016年接受上肢静脉双功超声检查的911例患者,其中182例(20.0%)诊断上肢深静脉血栓。30天内死亡30例(16.5%),6个月内死亡50例(27.5%),抗凝治疗与30天死亡率降低相关(OR 0.16)。

要点

  • 上肢深静脉血栓患者30天死亡率为16.5%,6个月为27.5%。
  • 抗凝治疗与30天死亡率降低独立相关(OR 0.16)。
  • 高龄、透析、抗凝高风险禁忌等合并症与死亡率增加相关。

核心结论

  • 上肢深静脉血栓患者死亡率较高,抗凝治疗与30天死亡率降低相关。
  • 死亡风险与多种合并症及人口学特征相关,并非仅由静脉血栓栓塞症本身导致。

研究设计与样本

  • 单中心回顾性研究,纳入2016年所有接受上肢静脉双功超声检查的患者共911例。
  • 其中182例(20.0%)诊断为上肢深静脉血栓,收集人口学、合并症、抗凝使用、血栓特征、治疗方案及结局资料。

主要发现

  • 30天内30例(16.5%)死亡,13例(7.1%)发生肺栓塞,42例(23.1%)发生肺栓塞或死亡,3例(1.6%)发生缺血性卒中。
  • 6个月内50例(27.5%)死亡。
  • 30天死亡率增加与高龄(OR 1.06)、抗凝高风险禁忌(OR 5.14)、透析(OR 3.03)、中心位置上肢深静脉血栓(OR 2.72)及卒中(OR 20.34)相关。
  • 抗凝治疗与30天死亡率降低相关(OR 0.16)。
  • 6个月死亡率增加与高龄(HR 1.05)、男性(HR 2.16)、透析(HR 2.90)、抗凝高风险禁忌(HR 2.67)、中心及外周静脉均累及的上肢深静脉血栓(HR 4.55)及30天内缺血性卒中(HR 71.63)相关。

临床怎么用

  • 对上肢深静脉血栓患者应评估抗凝治疗的可能性,抗凝与30天死亡率降低相关。
  • 需关注高龄、透析、抗凝高风险禁忌、中心位置血栓及卒中病史等高死亡风险因素。

局限性

  • 单中心回顾性研究,结果可能受选择偏倚影响。
  • 原文未报告抗凝方案的具体细节及长期随访数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Outcomes and the necessity for anticoagulation in patients with upper extremity deep vein thrombosis (UE DVT) are unclear. The purpose of this study was to determine the incidence of UE DVT, the outcomes of patients stratified by anticoagulation treatment, and which factors were significantly associated with mortality. METHODS: This study was a single-center, retrospective review of all patients undergoing UE venous duplex imaging in 2016. Information on patients' demographics, relevant comorbidities, use of anticoagulation at the time of diagnosis, characteristics of the UE DVT, treatment regimen(s), and outcomes was collected. Data were analyzed using descriptive and univariate statistics; multivariate logistic regression and Cox proportional hazard models were used to identify which of the aforementioned covariates are significantly associated with mortality rates at 30 days and 6 months, respectively, at a 95% confidence level. RESULTS: Of the 911 patients undergoing UE venous duplex imaging, 182 (20.0%) were positive for UE DVT. Within the first 30 days, 30 patients (16.5%) died, 13 (7.1%) had pulmonary emboli, 42 (23.1%) had either pulmonary emboli or died, and 3 (1.6%) had ischemic strokes. Within the first 6 months, 50 patients (27.5%) died. The mortality rate at 30 days was found to be significantly increased in patients who were older (odds ratio [OR], 1.06; P < .01), had high-risk contraindications to anticoagulation (OR, 5.14; P < .01), were on dialysis (OR, 3.03; P = .04), had centrally located UE DVTs (OR, 2.72; P < .05), and had a stroke (OR, 20.34; P = .03). Mortality was significantly decreased in patients who were treated with anticoagulation (OR, 0.16; P < .05). At 6 months, however, age (hazard ratio [HR], 1.05; P < .001), male sex (HR, 2.16; P = .02), dialysis (HR, 2.90; P = .01), high-risk contraindications to anticoagulation (HR, 2.67; P = .02), UE DVTs in both central and peripheral veins (HR, 4.55; P = .03), and ischemic stroke in the first 30 days (HR, 71.63; P < .001) were associated with significant increases in mortality. CONCLUSIONS: These data suggest that mortality rates among patients with UE DVT are relatively high and that treatment with anticoagulation is associated with a decrease in mortality at 30 days. Mortality was also associated with multiple comorbid conditions and demographics and not necessarily venous thromboembolism.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Beiswenger AC, Quereshy HA, Rouabhi M, et al. Midterm outcomes in patients with upper extremity deep vein thrombosis. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 32457023. doi:10.1016/j.jvsv.2020.02.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。